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Investigations of outbreaks of
multidrug-resistant tuberculosis have found low rates of
treatment response and very high mortality, and they
have mainly involved patients with advanced human im-
munodeficiency virus (HIV) infection. For patients without
HIV infection, one study reported an overall rate of re-
sponse to treatment of 56 percent, and the mortality from
tuberculosis was 22 percent. We investigated treatment
response and mortality rates in 26 HIV-negative patients




We obtained detailed data from seven
teaching hospitals in New York City on patients with
multidrug-resistant tuberculosis — defined as tubercu-
losis resistant at least to isoniazid and rifampin — who
were HIV-negative on serologic testing. Lengths of
times from diagnosis to the initiation of appropriate ther-
apy and from the initiation of appropriate therapy to con-
version to negative cultures were assessed. Therapeu-





Between March 1991 and September 1994,
26 HIV-negative patients were identified and treated. Of
the 25 patients for whom adequate data were available
for analysis, 24 (96 percent) had clinical responses; all 17
patients for whom data on microbiologic response were
available had such a response. The median times from
diagnosis to the initiation of appropriate therapy and from
the initiation of therapy to culture conversion were 44
days (range, 0 to 181) and 69 days (range, 2 to 705), re-
spectively. Side effects requiring the discontinuation of
medication occurred in 4 of 23 patients (17 percent) who
were treated with second-line antituberculosis medica-
tions. The median follow-up for the 23 patients who re-
sponded and who received appropriate therapy was 91




In this report from New York City, HIV-
negative patients with multidrug-resistant tuberculosis,
contrary to previous reports, responded well to appropri-
ate chemotherapy, both clinically and microbiologically.
(N Engl J Med 1995;333:907-11.)
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HE emergence of multidrug-resistant tuberculosis
has been well documented in both New York City




 Though New York
City had the highest rate in a national survey of report-
ed tuberculosis cases in the first quarter of 1991, cases
of multidrug-resistant tuberculosis were reported from




Previous studies have found that patients with drug-
resistant tuberculosis have lower response rates than





tigations of outbreaks of multidrug-resistant tuberculo-
sis have found an extraordinarily high case fatality rate,





 In almost all instances, these outbreaks
have involved patients severely immunosuppressed by
infection with the human immunodeficiency virus
(HIV). More recent data suggest that outcomes can be
improved if patients promptly start to receive two or





The expected outcome in patients not infected with
HIV who have multidrug-resistant tuberculosis is less
well defined. However, a widely cited study of 171 HIV-
negative patients treated from 1973 to 1983 at the Na-
tional Jewish Center for Immunology and Respiratory
Medicine found an overall response rate of 56 percent





In New York City, because of the recent dramatic in-
crease in cases of tuberculosis and multidrug-resistant
tuberculosis, we have had the opportunity to evaluate
patients with multidrug-resistant tuberculosis who are
not HIV-infected. We describe our experience with 25
patients whose clinical characteristics and outcomes dif-







We identified cases of multidrug-resistant tuberculosis — defined




 resistant at least to
isoniazid and rifampin — through a network of hospital-based physi-
cians who treat patients with tuberculosis at seven teaching hospitals
in New York City, including five private hospitals (Bronx–Lebanon
Hospital Center, Montefiore Medical Center, New York Hospital, St.
Clare’s Hospital, and Beth Israel Medical Center) and two public ones
(Harlem Hospital Center and North Central Bronx Hospital). Only
patients who were found to be HIV-negative by routine serologic test-
ing were included in the review. For patients who met these criteria,
detailed data-abstraction forms were completed by physicians at the
hospitals where the patients initially received the diagnosis of multi-
drug-resistant tuberculosis. The forms were designed to obtain infor-
mation on demographic characteristics, risk factors for tuberculosis
infection, the extent and verification of tuberculosis, and the response
to, and toxicity of, antituberculosis therapy.
The date of diagnosis of multidrug-resistant tuberculosis was de-
fined as the date of collection of the first specimen from which multi-
drug-resistant tuberculosis was isolated. The time to the initiation of
appropriate therapy was defined as the time from diagnosis to the in-
stitution of a regimen containing at least two drugs with in vitro ac-
tivity against the isolate. For one patient, appropriate therapy was be-
gun 63 days before the date of diagnosis. In the analysis, this patient
was assigned a value of zero days from diagnosis to appropriate treat-
ment. Another patient was in remission more than three years after
his initial diagnosis, without ever having received appropriate treat-
ment. He was removed from this analysis. The time to culture con-
version was defined as the time from the start of appropriate therapy
to the collection of the first in a series of two or more consecutive neg-
ative cultures at least two weeks apart. A therapeutic response was
evaluated on the basis of both microbiologic and clinical criteria. A
microbiologic response was defined as negative results of at least two
consecutive sputum cultures at least two weeks apart. A clinical re-
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sponse was defined as the resolution of signs and symptoms associat-
ed with the diagnosis of tuberculosis. Patients were considered to have
completed therapy if they had received a total of at least 18 months
of appropriate therapy or if they had received at least 12 months of
appropriate therapy after the conversion of their sputum cultures to
negative; 13 patients satisfied this criterion. Three additional patients
categorized as having completed therapy discontinued appropriate
treatment against medical advice after they had clinical or bacterio-
logic responses or both. The duration of follow-up was defined as the
interval between the date appropriate therapy was initiated and the




Standard procedures were used according to the practice of each





 and to test for susceptibility to first-line antituberculosis med-
ications, one hospital sent specimens to a commercial laboratory, and
one hospital sent specimens to the laboratories of the New York City
Department of Health. Bactec radiometric mediums (Becton Dickin-
son, Towson, Md.) were used by five of the laboratories, and solid




 Tests for susceptibility to py-
razinamide were not routinely performed until April 1992, and re-
sults are included here when they were available. Testing for suscep-
tibility to second-line antituberculosis medications and retesting for
susceptibility to first-line drugs were performed for 20 patients (80
percent) by a referral laboratory at one of four institutions: the Cen-
ters for Disease Control and Prevention, the New York City Depart-
ment of Health, the National Jewish Center for Immunology and





 For specimens tested by referral laboratories, multidrug resist-









g of rifampin per milliliter) of







Between March 1991 and September 1994, more
than 200 patients received diagnoses of multidrug-
resistant tuberculosis and were treated at the seven
hospitals. The overwhelming majority of these patients
were infected with HIV. During this interval, 26 HIV-
negative patients with multidrug-resistant tuberculosis
were identified and treated; for 25 of these adequate
data were available for analysis. Case finding was com-
plete at all seven hospitals. One hospital cared for sev-
en patients, one for six, one for four, one for three, two
for two, and one for one.
The demographic characteristics of the 25 patients
are shown in Table 1. The median age at the time of
diagnosis was 37 years, and 14 patients (56 percent)
were male. Fifteen patients (60 percent) were black,
four (16 percent) were Hispanic, four (16 percent) were
Asian, and two (8 percent) were white. Of the 10 pa-
tients born outside the United States or Puerto Rico,
5 were born in Asia, 3 in Latin America, 1 in Africa,
and 1 in Europe.
Previously established risk factors for multidrug-
resistant tuberculosis were identified in 17 of the pa-
tients (68 percent). Eight patients had a history of in-
adequately treated tuberculosis, and nine had known
exposures to patients with multidrug-resistant tubercu-
losis. Of these nine, eight were health care workers and
one was a patient hospitalized during a nosocomial out-
break of multidrug-resistant tuberculosis. Among the
health care workers, five were physicians, two were
nurses, and one was a medical administrator. An addi-
tional three patients were residents of the New York
City shelter system for the homeless.
All but four patients (84 percent) had disease local-
ized to the lung or pleura; one had both pulmonary and
peritoneal disease, and three had extrapulmonary dis-
ease alone (in the lymph nodes, the lumbar vertebrae,
and the soft tissues of the scrotum). Nineteen of the 25
patients had no underlying disease before the diagnosis
of tuberculosis; of the remaining 6, 2 had diabetes mel-
litus and end-stage renal disease, 2 had diabetes alone,
and 1 patient each had severe rheumatoid arthritis and
adenocarcinoma of the lung.
Twenty-four patients (96 percent) had clinical re-
sponses. One woman with diabetes mellitus and end-
stage renal disease died five days after standard doses
of isoniazid, rifampin, ethambutol, and pyrazinamide
were initiated. Results of susceptibility tests of her iso-
late became available post mortem and indicated resist-
ance to isoniazid, rifampin, streptomycin, and etham-
butol. No autopsy was performed, but the clinical
impression was that she died of overwhelming tubercu-
losis.
The patterns of susceptibility to the five first-line an-
tituberculosis medications and the treatment regimens
used for the 23 patients with responses who received
appropriate therapy are summarized in Table 2. Twelve
of the isolates (52 percent) were resistant to four or five
of the first-line antituberculosis agents. Eight patients
had isolates that were resistant to isoniazid and rifam-
pin only. Susceptibility testing was not done for pyra-
zinamide in eight patients.
Twenty-three patients who responded were ultimate-
ly treated with at least three drugs that had in vitro ac-
tivity against their isolates, and all received prolonged
treatment with a quinolone. Radiographic abnormali-
ties and clinical symptoms resolved without treatment
in the remaining patient with a response.
Three patients underwent therapeutic lobectomies at
the discretion of the primary treating physicians. Cul-
tures for one patient became negative only after a
lobectomy, despite approximately 15 months of appro-
priate chemotherapy. The other two patients had cul-
ture-negative sputum specimens before surgery, but
 
*The median age was 37 years.
 
Table 1. Demographic Characteristics of 25
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surgery was performed because of localized cavitary
disease found on chest radiography.
The median time from the diagnosis of multidrug-
resistant tuberculosis to the initiation of appropriate
therapy was 44 days (range, 0 to 181) for the 23 patients
who ultimately received at least three drugs with in vi-
tro activity against the multidrug-resistant isolate. All
17 patients for whom data on microbiologic response
were available had such responses. The median time to
a microbiologic response was 69 days (range, 2 to 705),
with a mean of 126 days. The mean was influenced by
two extreme values of 705 and 496 days. The first value
was that of a patient who was noncompliant for more
than 2 years but who subsequently responded after 90
days of appropriate therapy that was directly observed.
The patient with the second value responded only after
a lobectomy, despite appropriate and prolonged chemo-
therapy. All 17 patients who had microbiologic respons-
es also had clinical responses, with the resolution of
signs and symptoms.
Of the eight patients for whom microbiologic re-
sponse could not be determined, four did not have
follow-up specimens obtained because of the site of dis-
ease (lymph nodes, vertebrae, soft tissue of the scro-
tum, or pleura), and one patient died before follow-up
specimens could be obtained. Follow-up sputum speci-
mens were not obtained from three patients. Seven of
these eight patients had clinical responses.
As of March 31, 1995, 16 patients (64 percent) had
completed a course of therapy without evidence of re-
lapse (Table 3). Seven patients (28 percent) were in re-
mission while still receiving therapy, and one remained
in remission without having ever received appropriate
therapy. The 16 patients who had completed therapy
received quinolones for a median of 568 days (range,
150 to 787). In addition, 13 of these 16 patients received
parenteral therapy with either an aminoglycoside or
capreomycin (median, 252 days; range, 34 to 595);
8 received ethionamide (median, 570 days; range, 119
to 766); and 7 received cycloserine (median, 559 days;
range, 119 to 595).
The median duration of follow-up from the time that
appropriate therapy was instituted to the date of last
contact for the 23 patients with responses who received
treatment was 91 weeks (range, 41 to 225). For the 17
patients who had microbiologic responses, the median
duration of follow-up from the time of microbiologic re-
sponse was 81 weeks (range, 30 to 146). For the 16 pa-
tients who completed therapy, the median duration of
follow-up after the initiation of appropriate therapy was
121 weeks, and after the completion of therapy, 22
weeks (range, 0 to 52).
Eight patients had a history of tuberculosis; seven of
them completed therapy during the study period. These
patients had had tuberculosis for a median of 2.5 years
 
*The aminoglycosides used were streptomycin, kanamycin, and amikacin. For patients given more than one parenteral agent (aminoglycoside and capreomycin), the one given for the longer
course is indicated.










Two patients received four drugs; and one patient, three drugs. **Two patients received three drugs; two patients, four drugs; and two patients, five drugs.
 
Table 2. Profile of Susceptibility to First-Line Antituberculosis Drugs and Treatment Regimens for 23 Patients with Multidrug-Resistant


























































Isoniazid and rifampin 8§ 8 8 6 0 8 0 3 0 0
Isoniazid, rifampin, and 
streptomycin
1 1 1 0 1 1 0 1 1 0
Isoniazid, rifampin, and 
ethambutol
1 0 1 0 1 1 1 1 0 0
Isoniazid, rifampin, and
pyrazinamide
1 1 0 1 0 1 0 0 0 0
Isoniazid, rifampin, pyrazina-
mide, and ethambutol







0 2 2 0 3 2 1 1 0
Isoniazid, rifampin, pyrazina-
mide, and streptomycin




6** 0 0 1 4 6 6 5 1 1
 
*NA denotes not applicable. This patient died five days after admission
without receiving appropriate therapy.
 






























Completed a course of therapy and was 
without evidence of disease
16 (64) 121
Was under treatment and in remission 7 (28) 62
Was in remission without appropriate 
treatment
1 (4) 199
Died 1 (4) NA*
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1 to 6) and had received a median of 3.5 an-
tituberculosis drugs before the initiation of appropriate
therapy for their multidrug-resistant tuberculosis. The
median time to a microbiologic response in the 7 pa-
tients for whom data were available was 79 days, as
compared with 62 days in the 10 patients with available
data and no history of tuberculosis.
Serious side effects requiring the discontinuation of
second-line antituberculosis medication occurred in four
patients (17 percent) (Table 4). Nineteen patients had
no serious adverse reactions. In addition, 13 patients
had six or more months of parenteral therapy with
an aminoglycoside or capreomycin or both. Ototoxicity







Drug-resistant and multidrug-resistant tuberculosis
is a growing problem in the United States. The emer-










 The Centers for Disease Control and Pre-
vention conducted a nationwide susceptibility survey of
tuberculosis cases reported in 1991 and found that 14.2
percent were resistant to at least one drug and 3.5 per-
cent were resistant to both isoniazid and rifampin and




The optimal therapy for drug-susceptible tuberculo-
sis is well established after numerous trials comprising
thousands of patients. The optimal therapy for drug-
resistant tuberculosis, particularly multidrug-resistant
tuberculosis, is less well studied and standardized.
Mitchison and Nunn reviewed the outcomes of patients
with drug-resistant tuberculosis in 12 controlled trials





8212 patients studied, 1041 (12.7 percent) had tubercu-
losis with initial resistance to at least one drug and 256
(3.1 percent) had tuberculosis resistant to both isonia-
zid and streptomycin. Only 11 isolates were resistant to
rifampin. Chemotherapy failed in 5 of the 11 patients
with tuberculosis resistant to rifampin, and 3 of the re-
maining 6 patients relapsed after therapy was stopped.
These responses are in contrast to the high response
rates and few relapses that were seen in patients whose
disease was initially resistant to drugs other than rifam-
pin. The authors attributed these findings to the excel-
lent sterilizing activity of both rifampin and pyrazina-
mide and to the ability of rifampin to help prevent the
emergence of drug resistance during treatment.
A recently published study described the outcomes of
171 patients with multidrug-resistant tuberculosis treat-





patients had tuberculosis for a median of six years and
had received a median of six drugs before being re-
ferred to the National Jewish Center for Immunology
and Respiratory Medicine in Denver. Patients were
shedding tubercle bacilli that were resistant to a medi-
an of six drugs. Outcomes in this group were poor: of
134 patients for whom adequate follow-up data were
available, 87 (65 percent) initially responded to chemo-
therapy and 47 (35 percent) had no response, as mani-
fested by persistently positive cultures. The overall re-
sponse rate, including relapses, was 56 percent, and the
mortality attributable to tuberculosis was 22 percent.
In studies of outbreaks in the early 1990s, patients
with the acquired immunodeficiency syndrome (AIDS)
and multidrug-resistant tuberculosis had a median sur-




 In one report, those who were
HIV-infected but without a diagnosis of AIDS had a




 Recent reports have de-
scribed improved outcomes when HIV-infected patients





 In our series, the me-
dian time from the diagnosis of multidrug-resistant tu-
berculosis to the initiation of appropriate therapy was
44 days. This relatively short period, as compared with
those reported previously, is probably due to three fac-
tors: the practice of starting treatment with isoniazid,
rifampin, pyrazinamide, and ethambutol for all patients
with tuberculosis before the results of susceptibility test-
ing were available; the use of Bactec radiometric medi-
ums; and maintenance of a high index of suspicion for
drug-resistant tuberculosis.
We have shown that HIV-negative patients with mul-
tidrug-resistant tuberculosis can be expected to have a
good response to medical therapy. All of our patients
who received appropriate therapy have had clinical and
microbiologic responses. There were no relapses or
treatment failures during a median follow-up period of
91 weeks. It is still possible that some of these patients
will relapse. This group, however, in addition to having
the benefits of quinolone therapy, probably represents
patients of a different type from those described in the
Denver study. The Denver patients, as we have men-
tioned, were heavily pretreated and were referred after
treatment by physicians in their own communities had
failed. Many of our patients, on the other hand, proba-
bly had primary disease; in fact, only eight of the
patients (32 percent) had a history of tuberculosis.
 





6 months of parenteral aminoglycosides or capreomy-
cin or both.
 
Table 4. Side Effects of Second-Line Antitubercu-
losis Medications Leading to the Withdrawal of
















































-Aminosalicylic acid 1/4 Nausea 
Clofazimine 0/2 —
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As recent studies based on restriction-fragment–length
polymorphisms have demonstrated, recent transmis-
sion accounts for as much as 40 percent of cases of





may be that our results reflect the advantage of treating
primary resistant disease, rather than disease in per-
sons exposed intermittently to antituberculosis medica-
tion for years, resulting in secondary resistance and
damaged lungs. Even our patients with previous tuber-
culosis, all of whom responded, represented a group
different from those treated in the Denver series. They
had tuberculosis for a shorter period (2.5 years, vs. 6 for
the Denver patients) and were not as heavily pretreated
(median number of drugs, 3.5, vs. 6 in Denver). Lastly,
as we saw in one of our patients, primary tuberculosis,
even when due to a multidrug-resistant strain, may re-
solve with no effective chemotherapy, although the risk
of reactivation clearly remains.
Since this retrospective review is based on the experi-
ence of seven hospitals, laboratory techniques and treat-
ment regimens varied. Nevertheless, we conclude that
contrary to previous reports, patients without HIV infec-
tion who contract multidrug-resistant tuberculosis can
be expected to respond to appropriate chemotherapy,
both clinically and microbiologically. As in other studies,
serious drug toxicity is not unusual, and safer agents are
needed. Assessment of the long-term efficacy of this ap-
proach awaits several more years of patient follow-up.
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IMAGES IN CLINICAL MEDICINE




 feature, presents clinically important visual images, emphasizing those a
doctor might encounter in an average day at the office, the emergency department, or the hospital. If you have an
original unpublished, high-quality color or black-and-white photograph representing such a typical image that you
would like considered for publication, send it with a descriptive legend to Kim Eagle, M.D., University of Michigan
Medical Center, Division of Cardiology, 3910 Taubman Center, Box 0366, 1500 East Medical Center Drive, Ann Arbor,
MI 48109. For details about the size and labeling of the photographs, the requirements for the legend, and authorship,
please contact Dr. Eagle at 313-936-5275 (phone) or 313-936-5256 (fax), or the 
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